The Oncogenic Capacities of Long Noncoding RNA SNHG1 in Bladder Cancer by inducing proliferation and repressing apoptosis via upregulation of microRNA-9-3p-targeted MDM2

Weizhang Xu  
jiangsu cancer hospital

Yun Hu  
Jiangsu Cancer Hospital

Haifei Xu  
Nantong Tumor Hospital

Haofeng Liu  
nantong tumor hospital

Xiaolin Wang  
nantong tumor hospital

Qing Zou  
jiangsu cancer hospital

Xuejian Yang  
suqian first hospital

Hongzhou Cai (✉ caihong12006@163.com)  
jiangsu cancer hospital  https://orcid.org/0000-0001-8935-2093

Research

Keywords: Bladder cancer, Long noncoding RNA snhg1, microRNA-9-3p, MDM2, PPARγ, Proliferation, Tumorigenesis

DOI: https://doi.org/10.21203/rs.3.rs-141064/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The involvement of long noncoding RNA small nucleolar RNA host gene 1 (lncRNA SNHG1) was documented in numerous cancers, including bladder, pancreatic and prostate cancers. However, the further mechanistic investigation of SNHG1 in bladder is still needed to conduct. With this purpose, tissue, cell, and animal experiments were implemented in our research to figure out the specific mechanism of SNHG1 in bladder cancer via microRNA-9-3p (miR-9-3p).

Methods

In harvested bladder cancer tissues, RNA-FISH and RT-qPCR were adopted for SNHG1 expression measurement and RT-qPCR for miR-9-3p expression determination. The impacts of SNHG1, miR-9-3p, MDM2, and PPARγ on cell viability, proliferation, and apoptosis were evaluated by gain- and loss-of-function approaches. RT-qPCR and western blot analysis were performed to detect expression of MDM2, PPARγ, and apoptosis-related factors. RNA pull-down, RIP, dual luciferase reporter gene assay, and IP experiment were utilized to assess the modulatory relationship among SNHG1, miR-9-3p, MDM2, and PPARγ. Tumorigenic ability of bladder cancer cells was measured in vivo.

Results

High SNHG1 and poor miR-9-3p expression was identified in bladder cancer tissues and cells. Mechanistically, SNHG1 bound to miR-9-3p which negatively targeted MDM2. MDM2 augmented PPARγ ubiquitination to downregulate PPARγ. Bladder cancer cell proliferation was diminished and cell apoptosis was enhanced by silencing SNHG1 or MDM2 or overexpressing miR-9-3p. Similarly, SNHG1 silencing orchestrated miR-9-3p/MDM2/PPARγ axis to depress bladder cancer cell tumorigenesis in vivo.

Conclusion

In summary, the obtained data provided the novel insight of the anti-oncogenic mechanism of silencing SNHG1 in bladder cancer by activating PPARγ via downregulation of miR-9-3p-targeted MDM2.

Background

Bladder cancer (BC) ranks 9th on the list of cancers in terms of incidence with nearly 430000 cases of annual incidence, and ranks 13th among all cancers in yearly mortality across the world [1]. A strong male predominance is observed in bladder cancer, where three-fourths of cases occur in men [2]. The increased risk for bladder cancer correlates to factors including age, smoking, and exposure to some industrial chemicals [3]. The treatment of bladder cancer depends on stage and grade to a great extent,
which also strongly correlates to the prognosis of patients: the treatment of nonmuscle invasive bladder cancer is usually through resection and immunotherapy with intravesical drugs like Bacillus Calmette-Guerin, whilst more aggressive methods, like radical cystectomy coupled with chemotherapy, are needed for muscle invasive bladder cancer [4]. Unfortunately, bladder cancer is diagnosed generally the terminal stage, particularly in women, and there is little improvement in the treatment for bladder cancer with flat 5-year survival rate until recently [5]. Therefore, it is urgent to get a deeper understanding of molecular mechanism underlying bladder cancer, thus exploring a novel targets for bladder cancer treatment.

It is well-established that long noncoding RNA small nucleolar RNA host gene 1 (lncRNA SNHG1) is involved in advanced tumor node metastasis (TNM) and tumor stage and size, and reduced overall survival [6]. The oncogenic role of SNHG1 has been elucidated in various cancers. For instance, a prior study also reported the tumor-promoting potential of SNHG1 in pancreatic cancer with the results that SNHG1 silencing triggered repression of cell proliferative, metastatic, and invasive capacities by inactivating Notch-1 pathway [7]. In addition, Li et al. observed the suppressive effect of SNHG1 on prostate cancer development by promoting cell proliferation [8]. These evidences indirectly supported that SNHG1 might promote development of bladder cancer. Moreover, starbase website used in our study predicted the binding relationship between SNHG1 and microRNA-9-3p (miR-9-3p).

miR-9-3p (previously known as miR-9) is widely known for its altered expression and function in multiple diseases, like Huntington's disease and cancers [9]. Interestingly, it was detected that ectopically expressed miR-9-3p possessed antitumor potential in bladder cancer by diminishing cell invasion, migration, and proliferation [10]. In our study, the binding sites between miR-9-3p and 3’ untranslated region (UTR) of murine double minute 2 (MDM2) were predicted by TargetScan. MDM2 overexpression could reportedly neutralize the deressive effect of miR-379-5p on bladder cancer cell proliferative, migratory and invasive capacities [11]. In the presence of EGFR, MDM2 can bind to peroxisome proliferator-activated receptor-gamma (PPARγ) and regulate the ubiquitination of PPARγ protein in colon cancer cells [12]. More importantly, it was elaborated in a prior study that antagonist of PPARγ promoted cell cycle entry and decreased cell apoptosis in bladder cancer [13].

Taken these evidences into account, we hypothesized that SNHG1/miR-9-3p/MDM2/PPARγ axis correlated to the progression of bladder cancer. Therefore, the present study was implemented by focusing on the alteration in SNHG1 expression in bladder cancer tissues and cells and investigated the function and underlying mechanism of SNHG1 in bladder cancer progression via miR-9-3p/MDM2/PPARγ axis.

Materials And Methods

Compliance with ethical standards

The experiments involving human beings were implemented with ratification of Ethics Committee of Suqian First Hospital by conforming to the principles outlined in the Declaration of Helsinki. Ethical agreements were obtained from the donors or their families through written informed consent. Animal
experiments were ratified by Animal Ethics Committee of Suqian First Hospital and concurred with the Guidelines for Animal Experiments of Peking University Health Science Center.

**Study subject**

Forty patients with bladder cancer undergoing radical cystectomy in Suqian First Hospital from June 2016 to June 2017 were enrolled. Fresh bladder cancer tissues and corresponding adjacent normal tissues were preserved in liquid nitrogen immediately subsequent to resection. None of patients received preoperative radiotherapy, chemotherapy or immunotherapy. Follow-up information was obtained from outpatient clinics and regular telephone interviews.

**Bioinformatics methods**

Gene Expression Profiling Interactive Analysis (GEPIA) was adopted to analyze the BLCA dataset of The Cancer Genome Atlas (TCGA) database to obtain the genes with significant differences \((p < 0.05)\), from which the genes with \(|\log\text{FC}| > 0.5\) were screened out. The Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/gds) was also analyzed by using "limma" package (http://www.bioconductor.org/packages/release/bioc/html/limma.html) of the R language with \(|\log\text{FC}| > 0.5\) and \(p < 0.05\) as thresholds for differential analysis of bladder cancer microarray data GSE65635 and GSE40355. There were 12 samples in microarray data GSE65635, including 4 normal samples and 8 bladder cancer samples. There were 24 samples in microarray data GSE40355, including 8 normal samples and 16 bladder cancer samples. Human IncRNA names were obtained from GENCODE, followed by obtaining of the intersection of significantly differential genes and IncRNA names. Venn diagram was drawn to screen out the IncRNAs among intersection. LncRNA expression trends were collected in Ualcan, and the key IncRNA was determined by comparing the expression trends and combining with the existing literature. The possible downstream miR of the key IncRNA was discovered by starBase and their binding sites were obtained. The databases TargetScan (Cumulative weighted context++ score < 0), DIANA TOOLS (miTG score > 0.6), microRNA (conservation > 0.65, energy < -14, Mirsvr_score < -0.65), and mirDIP (Integrated Score > 0.1) was applied to predict downstream genes of miR. Intersection of downstream genes with significantly differential genes was taken to obtain critical downstream gene. The relevant genes of the critical downstream gene were predicted in GeneMANIA (http://genemania.org/), followed by construction of protein-protein interaction (PPI) network. The most core genes in PPI network were chosen as the key gene, and the binding sites of the miR to the gene were predicted by TargetScan.

**Fluorescence in situ hybridization (FISH)**

SNHG1 cDNA fragments were amplified from the SNHG1 plasmid as templates by utilizing high fidelity DNA polymerase (Takara, Kyoto, Japan). Based on this template, fluorescein-labeled IncTCF7 FISH probe DNA was prepared with fluorescein-12-dUTP (Roche, Mannheim, Germany) and Klenow DNA polymerase as per the manufacturer's protocol. Four-µm frozen sections were made from bladder cancer tissues and adjacent normal tissues. Subsequent to 5-min immersion in proteinase K, the slides were washed twice in 2 × saline sodium citrate (SSC). The FISH hybridization solution encompassing 30 ng/µL IncTCF7 FISH
probe DNA (Beijing Dingguo Changsheng Biotechnology Co., Ltd., Beijing, China) was dripped onto the tissue sections before 16-h incubation at 37°C. The slides were then washed in 0.4 × SSC/0.001% NP-40 for 5 min at 56°C, followed by another 2-min washing in 0.4 × SSC/0.001% NP-40. After being dripped with 4',6-Diamidino-2-Phenylindole (DAPI)-encompassing sealing agent, the slide was mounted and observed under a fluorescence microscope (Olympus, Tokyo, Japan).

Cell incubation

Human normal urothelial cell line SV-HUC-1 (ATCC® CRL-9520), and bladder cancer cell lines [5637 (ATCC® HTB-9), T24 (ATCC® HTB-4™), SW780 (ATCC® CRL-2169™), and UM-UC-3 (ATCC® CRL-1749™) were attained from American Type Culture Collection (ATCC, Manassas, VA, USA). The medium used for SV-HUC-1 was ATCC-formulated F-12K Medium (Catalog No. 30-2004) encompassing 10% fetal bovine serum (FBS, ATCC 30-2020). The medium used for 5637 was ATCC-formulated RPMI-1640 Medium (ATCC 30-2001) encompassing 10% FBS. The medium for T24 was ATCC-formulated McCoy's 5A Medium Modified (Catalog No. 30-2007) with 10% FBS. The medium for SW780 was ATCC-formulated Leibovitz's L-15 Medium (Catalog No. 30-2008) with 10% FBS. The medium for UM-UC-3 was ATCC-formulated Eagle's Minimum Essential Medium (Catalog No. 30-2003) with 10% FBS. All media for cell lines encompassed 100 μg/mL streptomycin and 100 U/mL penicillin. Cell culture was performed at 37°C with 5% CO₂. The media were positioned in humid air and replaced every 2-3 days according to the growth of cells. Cells were subcultured when 80%-90% of the culture plate was covered by cells. Cells were utilized when they reached the logarithmic growth stage.

Cell transfection

Lentiviruses expressing specific targeted knockdown SNHG1 [short hairpin-SNHG1 (sh-SNHG1)] and MDM2 (sh-MDM2) sequences and a scramble shRNA (sh-NC; control shRNA) were constructed by GenePharma (Shanghai, China) (Table 2). Lentiviruses overexpressing SNHG1 (oe-SNHG1), MDM2 (oe-MDM2), and PPARγ (oe-PPARγ), oe-NC, Inhibitor NC, and miR-9-3p inhibitor were obtained from GenePharma. Transfection was implemented using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA).

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Subsequent to isolation using RNeasy Mini Kit (Qiagen, Valencia, CA, USA), total RNA underwent reverse transcription to generate cDNA using First Strand cDNA Synthesis Kit (RR047A, Takara). For the detection of miR, the cDNA was obtained by reverse transcription using the miRNA First Strand cDNA Synthesis (Tailing Reaction) kit (B532451-0020, Sangon, Shanghai, China). RT-qPCR reactions were performed using SYBR® Premix Ex TaqTM II (Perfect Real Time) kit (DRR081, Takara) on real-time fluorescence quantitative PCR instrument (ABI 7500, Applied Biosystems, Foster City, CA, USA). The universal reverse primers for miR and the upstream primers for U6 internal reference were provided in the miRNA First Strand cDNA Synthesis (Tailing Reaction) kit, and the other primers were synthesized by Sangon. (Table 3). After recording of the Ct value of each well, the relative expression of mRNAs or miR was calculated.
using the $2^{\Delta\Delta Ct}$ method by normalizing to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or U6 expression.

**Cell counting kit (CCK)-8 assay**

The transfected T24 and 5367 cells were resuspended and seeded in 96-well plates at $2 \times 10^3$/100 µL/well. Cell viability was evaluated by CCK-8 (Dojindo Laboratories, Kumamoto, Japan) method at 0, 24, 48, 72 and 96 h after seeding. The 10 µL CCK-8 solution was supplemented in each test for 4-h incubation before absorbance measurement at 450 nm with a microplate reader.

**5-ethynyl-2'-deoxyuridine (EdU) assay**

The cells to be tested were seeded in 24-well plates with three duplicated wells set for cells in each group. EdU (Invitrogen) was supplemented to the medium to achieve a concentration of 10 µmol/L. The medium was discarded subsequent to 2-h culture. Cells received 15-min phosphate buffer saline (PBS) encompassing 4% paraformaldehyde fixing at ambient temperature before 20-min incubation at ambient temperature with PBS encompassing 0.5% Triton-100. Each well was supplemented with 100 µL dye solution before 30-min culture in the dark at ambient temperature. DAPI was added for 5-min nuclear staining. After sealing, 6-10 fields of view were randomly observed under a fluorescence microscope (FM-600, Shanghai Pudan Optical Instrument Co., Ltd., Shanghai, China), and the number of positive cells in each field was recorded.

**Flow cytometry**

Subsequent to 48-h transfection, the cell concentration was changed to $1 \times 10^6$ cells/mL. Subsequent to cell fixing with 70% precooled ethanol solution at 4°C, 100 µL cell suspension (no less than $1 \times 10^6$ cells/mL) was resuspended in 200 µL binding buffer. Subsequently, 15-min cells staining were implemented with 10 µL Annexin V-fluoresceinisothiocyanat and 5 µL propidium iodide at ambient temperature under dark conditions. After 300 µL of binding buffer was added, apoptosis was assessed on a flow cytometer at excitation wavelength of 488 nm ($2 \times 10^4$ cells each time).

**Western blot analysis**

Subsequent to trypsin treatment, cells were lysed with enhanced radio-immunoprecipitation assay (RIPA) lysis encompassing protease inhibitors (BOSTER, Wuhan, Hubei, China), followed by estimation of protein concentration using Bicinchoninic Acid (BCA) Protein Quantification Kit (BOSTER). Proteins underwent separation by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Then, the separated proteins were electroblotted into a polyvinylidene fluoride (PVDF) membrane which was sealed by 5% bovine serum albumin to block nonspecific binding. Overnight cell incubation was conducted at 4°C after supplementation with primary rabbit antibodies (Abcam, Cambridge, UK) to Cleaved caspase-3 (ab49822, 1: 500), Bcl-2-Associated X (Bax, ab32503, 1: 1000), B-cell lymphoma-2 (Bcl-2, ab196495, 1: 500), MDM2 (ab226939, 1: 3000), PPARγ (ab45036, 1: 500), Ubiquitin (ab7780, 1: 500).
2000), and β-actin (ab8227, 1: 500). Then, horseradish peroxidase-tagged goat anti-rabbit secondary antibodies (ab205719, 1: 2000, Abcam) were supplemented for 1-h membrane incubation at 4°C. After development in ECL working uid (EMD Millipore Corporation, Billerica, USA), the bands in western blot images were quantified by Image J analysis software by normalizing to β-actin.

**RNA pull down**

Cells were transfected with biotinylated wild type (WT) miR-9-3p and mutant type (MUT) miR-9-3p (50 nM each). After 48 h of transfection, 10-min cell incubation was implemented with specific cell lysis (Ambion, Austin, Texas, USA). Then, 3-h lysate incubation was conducted with M-280 streptavidin magnetic beads (Sigma, St. Louis, MO, USA) pre-coated with RNase-free and yeast tRNA at 4°C before two cell washes in cold lysis and RT-qPCR detection of SNHG1 expression.

**RNA immunoprecipitation (RIP) assay**

The binding of miR-9-3p to MDM2 was detected by RIP kit (Millipore, Temecula, CA, USA). Briefly, 5-min cell lysing was implemented in an ice bath with equal volume of RIPA lysis (P0013B, Beyotime, Shanghai, China), and supernatant was removed subsequent to 10-min centrifugation at 14000 rpm and 4°C. A portion of the cell extract was applied as input, and a portion was co-precipitated with antibody. RNA exaction was implemented by treating samples with proteinase K for subsequent RT-qPCR detection of MDM2. Antibodies used for RIP were as follows: rabbit anti-Argonaute 2 (AGO2) (1: 100, ab32381, Abcam) was mixed at ambient temperature for 30 min, and rabbit anti-human Immunoglobulin G (IgG; 1: 100, ab109489, Abcam) was applied as a NC.

**Dual luciferase reporter gene assay**

The synthesized MDM2 3’ untranslated region (UTR) gene fragment MDM2-WT and the MDM2-MUT mutated at the binding site were constructed into a pMIR-reporter plasmid (Beijing Huayueyang Biotechnology, Beijing, China). Luciferase reporter plasmids were co-transfected with miR-9-3p into HEK293T cells (Shanghai Beinuo Biotechnology, Shanghai, China). Forty-eight h subsequent to transfection, cells were lysed, and detected using a luciferase detection kit (K801-200; Biovision, Mountain View, CA, USA).

**Immunoprecipitation (IP)**

Cells were lysed in lysis buffer [mixture of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10% glycerol, 1 mM ethylene diamine tetraacetic acid, 0.5% NP-40, and protease inhibitor], and cell debris was cleared by centrifugation. After the concentration of lysis was measured by BCA, the same amount of protein was taken from each experimental group and replenished to the same volume with cell lysate. Afterwards, 1 μg anti-MDM2 (ab226939, 1: 100, Abcam), PPARγ (ab45036, 1: 100, Abcam) and 15 μL protein A/G beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were added for 2-h incubation. Subsequent to three washes with cell lysis, beads were collected by centrifugation, added into an equal volume of
reductive loading buffer, and boiled at 100°C for 5 min. Subsequent to SDS-PAGE, samples were electroblotted to PVDF membranes (Millipore), and then analyzed by immunoblotting.

**Subcutaneous tumorigenesis model in nude mice**

Healthy nude mice aged 6-8 weeks (Beijing Institute of Pharmacology, Chinese Academy of Medical Sciences, Beijing, China) were bred in specific pathogen-free animal laboratory with 60%-65% humidity at 22-25°C. They were fed in separate cages under 12:12-h light-dark cycle with food and water available ad libitum. The experiment was started one week after acclimation, and the health status of nude mice was observed before the experiment. Approximately $2 \times 10^6$ cells were suspended in 200 μL PBS, and then subcutaneously injected into the left or right hindlimbs of nude mice (10 mice/group). At 28 days subsequent to injection, mice were euthanized, followed by measurement and weighing of tumors.

**Statistical analysis**

All measurement data were manifested as mean ± standard deviation and analyzed by SPSS 21.0 software (IBM, Armonk, NY, USA), with $p < 0.05$ as a level of statistically significance. If data conformed to normal distribution and homogeneity of variance, data within groups were compared by paired t test, while data between two groups were compared by unpaired t test. Comparisons among multiple groups were performed using one-way analysis of variance (ANOVA) or repeated measures ANOVA. Intra-group pairwise comparison was performed using post-hoc test. Rank sum test was performed if data did not conform to normal distribution or homogeneity of variance. Kaplan-Meier was adopted to calculate patient survival curves, and log-rank was utilized to analyze patient survival differences.

**Results**

**SNHG1 was highly expressed in bladder cancer tissues and associated with poor prognosis of patients with bladder cancer**

The BLCA data of TCGA database were analyzed by GEPIA to obtain 6597 significantly differential genes ($|\log FC| > 0.5, p < 0.05$) (Fig. 1A). Then, R language was employed for difference analysis of microarray data GSE65635 and GSE40355 in GEO database to obtain 4283 and 8065 significantly differential genes, respectively ($|\log FC| > 0.5, p < 0.05$). Then, 17937 human IncRNA names were obtained from GENCODE, which were intersected with differential genes. It was found that only DIO3OS and SNHG1 were significantly differential IncRNAs in bladder cancer (Fig. 1B). Analysis of TCGA database data by Ualcan revealed that DIO3OS was significantly underexpressed in bladder cancer ($p = 1.949E-05$; Fig. 1C), while SNHG1 was significantly overexpressed in bladder cancer ($p = 3.889E-11$; Fig. 1D). Moreover, the difference of SNHG1 was significantly higher than that of DIO3OS. There was literature indicating the upregulation of SNHG1 in thyroid cancer [14], non-small cell lung cancer (NSCLC) [15], colorectal cancer [16, 17], but SNHG1 was not studied in bladder cancer. Next, RNA-FISH showed high SNHG1 expression in bladder cancer tissues compared with adjacent normal tissues (Fig. 1E). Further detection by RT-qPCR assay also found that SNHG1 was highly expressed in bladder cancer tissues (Fig. 1F), and that patients
with high expression of SNHG1 had worse prognosis (Fig. 1G). Therefore, high SNHG1 expression was associated with poor prognosis of patients with bladder cancer.

**SNHG1 was highly expressed in bladder cancer cells and promotes bladder cancer cell proliferation**

To further examine the regulatory role of SNHG1 in bladder cancer, we selected one normal urothelial cell line SV-HUC-1 and four bladder cancer cell lines (5637, T24, SW780, and UM-UC-3). As described in Fig. 2A, SNHG1 expression was increased in cancer cells compared with SV-HUC-1 cells. Subsequent experiments were conducted on T24 cells with higher SNHG1 expression and 5637 cells with lower SNHG1 expression. After silencing SNHG1 in T24 cell (Fig. 2B), the shRNA with the highest silencing efficiency was selected for subsequent experiments. CCK-8 and EdU assays exhibited that the viability and proliferation of T24 cells were obviously inhibited by treatment with sh-SNHG1 (Fig. 2C-D). The apoptotic rate of T24 cells elevated significantly (Fig. 2E), accompanied by prominent increase of Cleaved caspase-3 and Bax expression and remarkable decline of Bcl-2 expression (Fig. 2F) after silencing SNHG1. It suggested that silencing SNHG1 could trigger the inhibition of cell proliferation and promotion of cell apoptosis in bladder cancer. Further experiments in 5637 cells manifested that overexpression of SNHG1 in 5637 cells (Fig. 3A) noteworthy enhanced viability (Fig. 3B) and proliferation (Fig. 3C), diminished apoptosis (Fig. 3D), and reduced the expression of Cleaved caspase-3 and Bax but elevated Bcl-2 expression (Fig. 3E). Collectively, SNHG1 upregulation promoted the proliferation of bladder cancer cells.

**SNHG1 promotes bladder cancer cell tumorigenesis in Vivo**

Further, a subcutaneous tumorigenic model was established in nude mice to detect the tumorigenic ability of bladder cancer cells in vivo. RT-qPCR depicted that SNHG1 expression was appreciably decreased in mice treated with sh-SNHG1 (Fig. 4A). In addition, the growth rate and weight of tumors were appreciably decreased after silencing SNHG1 (Fig. 4B). FISH experiment illustrated that SNHG1-silenced mice had distinct decline of SNHG1 expression (Fig. 4C). On the contrary, overexpression of SNHG1 (Fig. 4D) contributed to the appreciable elevation of the growth rate and weight of tumors (Fig. 4E) and SNHG1 expression in tumors (Fig. 4F). In summary, SNHG1 overexpression promoted bladder cancer cell tumorigenesis in vivo.

**SNHG1 silencing suppressed bladder cancer cell proliferation and tumorigenesis by binding to MiR-9-3p**

Then, we explored the downstream miR of SNHG1 in bladder cancer. RNA-FISH (Fig. 1B) showed that SNHG1 was localized in the cytoplasm, suggesting that SNHG1 may be involved in the process of bladder cancer by affecting miR. The Starbase website predicted that SNHG1 could bind to miR-9-3p (Fig. 5A). A previous study has reported that miR-9-3p expression is poor in bladder cancer [10], but the related regulatory mechanisms need further study. RT-qPCR revealed that miR-9-3p expression was significantly low in bladder cancer tissues (Fig. 5B) and had significantly inverse correlation with the expression of SNHG1 (Fig. 5C). Meanwhile, it was verified by RNA pull-down that SNHG1 indeed bound to miR-9-3p (Fig.
5D). In addition, silencing SNHG1 in T24 cells prominently increased miR-9-3p expression (Fig. 5E), while overexpressing SNHG1 in 5637 cells severely declined miR-9-3p expression (Fig. 5F).

The effect of SNHG1 binding to miR-9-3p on bladder cancer cells was further examined. Silencing SNHG1 alone resulted in decrease of SNHG1 expression. Besides, silencing SNHG1 alone reduced cell proliferation, increased apoptotic rate, elevated Cleaved caspase-3 and Bax expression, and declined Bcl-2 expression in T24 cells, which was opposite after treatment with miR-9-3p inhibitor alone. However, co-treatment with sh-SNHG1 and miR-9-3p inhibitor reversed the effect of sh-SNHG1 or miR-9-3p inhibitor alone (Fig. 6A-E). Simultaneously, in vivo experiments showed that the tumorigenic ability of bladder cancer cells in vivo was diminished by treatment with sh-SNHG1 alone and elevated by treatment with miR-9-3p inhibitor alone, which was neutralized by co-treatment with sh-SNHG1 and miR-9-3p inhibitor (Fig. 6F, G). Conclusively, silencing SNHG1 bound to miR-9-3p to inhibit bladder cancer cell proliferation and tumorigenesis.

**Silencing SNHG1 decreased MDM2 expression through MiR-9-3p**

Subsequently, the downstream target genes of miR-9-3p were investigated. The 3615, 2399, 270 and 2387 downstream genes of miR-9-3p were respectively predicted in TargetScan, DIANATOOLS, microRNA and mirDIP, and then were intersected. The intersecting results were compared with the differential genes in bladder cancer obtained by GEPIA, which screened out 21 significantly differential downstream genes of miR-9-3p (Fig. 7A). By constructing the PPI network through GeneMANIA, we found that MDM2 had the highest core degree in the PPI network and was double the core degree of second-ranked genes (Fig. 7B, Table 1). The binding site of miR-9-3p in MDM2 3'UTR was predicted using TargetScan (Fig. 7C).

Nevertheless, previous studies detected that MDM2 was highly expressed as a proto-oncogene in bladder cancer [11, 18]. miR-9-3p may be involved in the progression of bladder cancer by inhibiting the expression of MDM2, which was further verified by experiments. Firstly, AGO2 pulled down MDM2 in RIP experiments (Fig. 7D). Dual luciferase reporter assay manifested that miR-9-3p mimic markedly inhibited the luciferase activity of MDM2 WT, but had no obvious effect on the luciferase activity of MDM2 MUT, suggesting that miR-9-3p bound to the 3'UTR of MDM2 (Fig. 7E).

After sh-SNHG1 and miR-9-3p inhibitor were co-transfected into T24 cells, MDM2 expression was evaluated by RT-qPCR and western blot analysis. As displayed in Fig. 7F, G, MDM2 expression was noticeably decreased after silencing SNHG1 alone, and observably increased after transfection with miR-9-3p inhibitor alone, which was normalized by co-treatment with sh-SNHG1 and miR-9-3p inhibitor. It was suggested that silencing of SNHG1 inhibited MDM2 expression through binding to miR-9-3p.

**SNHG1 silencing led to suppression of proliferation and tumorigenesis of bladder cancer cells by downregulating MDM2**

Further, the expression of MDM2 was overexpressed in SNHG1-silenced T24 cells. From RT-qPCR results, the expression of SNHG1 and MDM2 was substantially diminished and miR-9-3p expression was significantly enhanced after silencing SNHG1 alone. MDM2 expression was appreciably increased after
overexpressing MDM2 alone, and silencing SNHG1 negated the effect of overexpressing MDM2 (Fig. 7H). As described in Fig. 7I, J, CCK-8 and EdU assays exhibited that silencing SNHG1 appreciably reduced but overexpressing MDM2 increased cell proliferation, and overexpressing MDM2 could reverse the effect of silencing SNHG1 on cell proliferation (Fig. 7I-J). To sum up, SNHG1 silencing suppressed the proliferation of bladder cancer cells by decreasing MDM2 expression through miR-9-3p.

Further in vivo validation was carried out. The expression of SNHG1, miR-9-3p, and MDM2 was detected by RT-qPCR. As presented in results, SNHG1 and MDM2 expression was strikingly declined and miR-9-3p expression was remarkably elevated after silencing SNHG1. MDM2 expression was prominently promoted after overexpressing MDM2, and overexpressing MDM2 could reverse the effect of silencing SNHG1 on MDM2 expression (Fig. 7K). Furthermore, after silencing SNHG1 alone, tumor growth was repressed, and after overexpressing MDM2 alone, tumor growth was promoted. Overexpression of MDM2 abrogated the effect of silencing SNHG1 on tumor growth (Fig. 7L). In summary, silencing SNHG1 decreased the tumorigenesis of bladder cancer cells in vivo by decreasing MDM2 expression through miR-9-3p.

**Silencing SNHG1 upregulated PPARγ through MDM2**

It has been documented that after addition of EGFR, MDM2 can bind to PPARγ and regulate the ubiquitination of PPARγ protein in colon cancer, and that MDM2 silencing can increase the level of PPARγ [12], which is further verified in bladder cancer. Firstly, through IP experiments in T24 cells, it was found that MDM2 and PPARγ combined with each other (Fig. 8A). Further, after screening out the MDM2 silencing sequence (Fig. 8B, sh-MDM2-3 was selected for subsequent experiments), we found that PPARγ ubiquitination decreased and PPARγ expression increased after silencing MDM2 with the addition of EGFR (Fig. 8C), which was opposite after overexpressing MDM2 (Fig. 8D). MDM2 was overexpressed after silencing SNHG1 in T24 cells with the addition of EGFR. Western blot analysis exhibited that MDM2 expression was prominently decreased and PPARγ expression was severely elevated after silencing SNHG1 alone, which was opposite after overexpressing MDM2 alone. Silencing SNHG1 annulled the effect of overexpressing MDM2 on MDM2 and PPARγ expression (Fig. 8E). The above results suggested that MDM2 reduced PPARγ expression by inducing PPARγ ubiquitination, while silencing of SNHG1 elevated PPARγ expression through downregulating MDM2.

**Discussion**

As one of the most prevalent genitourinary cancers with high mortality on a global scale, bladder cancer currently can be treated with appended by local or systemic immunotherapy, radiotherapy, chemotherapy, and endoscopic and open surgery [19]. However, the curative effect of such therapies is limited because of recurrence or distant spread [20]. Moreover, IncRNAs has been emerged as a modulator in the complexity of bladder cancer [21]. Consequently, this research was intended to rule of the mechanism of SNHG1 in bladder cancer with the involvement of miR-9-3p. Notably, the present study provided evidence that SNHG1 promotes MDM2 expression by binding to miR-9-3p to promote PPARγ ubiquitination and
downregulate PPARγ expression, thereby resulting in elevation of bladder cancer cell proliferation \textit{in vitro} and tumorigenesis \textit{in vivo}.

Initially, data from our study unraveled that SNHG1 was highly expressed in bladder cancer tissues and cells. Additionally, when SNHG1 was silenced in bladder cancer cells and mice, cell proliferative capacity was depressed but cell apoptosis was accelerated in vitro, and tumorigenesis was inhibited in vivo. Importantly, SNHG1 has emerged as a novel oncogenic IncRNA in various cancers, including esophageal, colorectal, prostate, gastric, liver, and lung cancers by inducing cell proliferative, metastatic, migratory and invasive capacities of cancer cells [6]. Consistently, Lu \textit{et al.} observed that SNHG1 expression was strikingly high in NSCLC tissues and cells, and that SNHG1 silencing decreased tumor volumes in mice and reduced NSCLC cell proliferation, invasion and migration [22]. Meanwhile, data collected by Bai \textit{et al.} found that SNHG1 expression was upregulated in colorectal cancer cells, and that ectopically expressed SNHG1 could enhance cell migratory, proliferative, and invasive capacities in vitro and led to tumor growth [23, 24]. Another study uncovered that SNHG1 silencing contributed to decline of tumor growth of breast cancer \textit{in vivo} [25]. These findings indirectly supported the tumor-promoting potential of SNHG1 in bladder cancer by enhancing cell proliferation and tumor growth and reducing apoptosis.

It is well-recognized that lncRNAs may function as endogenous sponges to regulate miRNA function in diseases [26]. For example, a prior research displayed that SNHG1 could bind to miR-204 to inhibit it, thus promoting migratory, and invasive abilities but repressing apoptosis in esophageal squamous cell cancer [27]. These findings indirectly confirmed the binding relationship between SNHG1 and miR-9-3p in bladder cancer cells which observed by our study. Further investigations of our study identified that miR-9-3p inhibition led to increase of cell proliferation and decrease of apoptosis in vitro and promotion of tumorigenesis \textit{in vivo} and reversed the effect of SNHG1 silencing in bladder cancer. Similarly, a research conducted by Cai \textit{et al.} clarified that in bladder cancer, miR-9-3p overexpression triggered repression of cell viability, migration, and invasion, induction of cell apoptosis in vitro, and inhibition in vivo tumor growth and metastasis [10]. Notably, another study illustrated that miR-9-3p exerted tumor-suppressive effect on hepatocellular carcinoma by depressing hepatocellular carcinoma cell proliferation [28], which was in line with our results. Hence, these results confirmed that SNHG1 overexpression promoted bladder cancer progression by binding to miR-9-3p.

It is well-established that miRs inhibit expression of target genes at post-transcriptional level by targeting the 3’UTR of mRNA [29]. As previously reported, miR-9-3p targeted HBGF-5 to function as a tumor suppressor in hepatocellular carcinoma [30]. Moreover, in our study, TargetScan website predicted the binding sites between miR-9-3p and MDM2 3’UTR, and then the targeting relationship between miR-9-3p and MDM2 was verified by dual luciferase reporter gene assay. In the subsequent experiments, we found that MDM2 bound to PPARγ and downregulated PPARγ by inducing PPARγ ubiquitination, which was similar to the results observed by Xu \textit{et al.} [12]. Furthermore, our data elaborated that MDM2 ectopic expression neutralized the inhibitory effect of SNHG1 silencing on cell proliferation in vitro and tumor growth in vivo and the promoting effect of SNHG1 silencing on cell apoptosis in vitro in bladder cancer, suggesting the oncogenic role of MDM2 in bladder cancer. Consistently, a prior study uncovered that
inhibition of MDM2 exerted tumor-suppressive effects on bladder cancer by decreasing cell invasive, proliferative, and migratory capacities [11]. Accordingly, PPARγ activation gave rise to inhibition of proliferation of 9 bladder cancer cell lines [31] All in all, the SNHG1/miR-9-3p/MDM2/PPARγ axis was involved in bladder cancer progression.

**Conclusion**

Collectively, this study provides evidence that SNHG1 upregulation promoted cell proliferation but depressed cell apoptosis in bladder cancer via MDM2-inhibited PPARγ by binding to miR-9-3p (Fig. 9). Thus, this finding offers a fresh molecular insight that might be utilized in new therapy development for bladder cancer. However, further studies are prerequisites on the mechanism of PPARγ in bladder cancer.

**Abbreviations**

TNM: tumor node metastasis; UTR: untranslated region; MDM2: murine double minute 2; PPARγ: peroxisome proliferator-activated receptor-gamma;

**Declarations**

**Acknowledgements**

We would like to acknowledge the colleagues for their helpful assistance on this study.

**Conflict of interest**

All authors declare that they have no conflict of interest.

**Author contributions**

HZC conceived and designed research. WZX, YH and HFX performed experiments. HFL analyzed data. XLW interpreted results of experiments. QZ prepared Figures. WZX, YH and HFX drafted manuscript. XJY and HZC edited and revised manuscript.

**Availability of data and materials**

All data that support the findings of this study are available from the corresponding authors upon reasonable request.

**Funding**

This study was supported by Nantong Science and Technology Plan (No. MS22019010).

**Competing interest**
The authors declare no conflict of interest.

References


Tables

Table 1 sh-RNA sequences for transfection

<table>
<thead>
<tr>
<th>shRNAs</th>
<th>Sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>sh-SNHG1#1</td>
<td>5′-GCTGAAGTTACAGGTCTGA-3′</td>
</tr>
<tr>
<td>sh-SNHG1#2</td>
<td>5′-GACCTAGCTTGTTGCAAT-3′</td>
</tr>
<tr>
<td>sh-SNHG1#3</td>
<td>5′-GCTGAAGTTACAGGTCTGA-3′</td>
</tr>
<tr>
<td>sh-MDM2#1</td>
<td>5′-GCTTCGGAACAAGAGACTC-3′</td>
</tr>
<tr>
<td>sh-MDM2#2</td>
<td>5′-GGAGCAGGCAATGTGCAATA-3′</td>
</tr>
<tr>
<td>sh-MDM2#3</td>
<td>5′-GGAACCTTGGTAGTAGTCAATC-3′</td>
</tr>
<tr>
<td>sh-NC</td>
<td>5′-TTCTCCGAACGTGCACGTTT-3′</td>
</tr>
</tbody>
</table>

Table 2 Primer sequences for RT-qPCR

<table>
<thead>
<tr>
<th>Targets</th>
<th>Forward Primer (5′-3′)</th>
<th>Reverse Primer (5′-3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNHG1</td>
<td>GCCAGCACCTTCTCTCTAAAGC</td>
<td>GTCCTCAAGACAGATTCCATTTC</td>
</tr>
<tr>
<td>miR-9-3p</td>
<td>GGAGACCGGAAATGTGACCA</td>
<td>AATGGGCGCTGGAGTCTTTT</td>
</tr>
<tr>
<td>MDM2</td>
<td>GCAGTGAATCTACAGGGACGC</td>
<td>ATCCTGATCCACCAATCACC</td>
</tr>
<tr>
<td>U6</td>
<td>CTCGCTTTGCAGCACA</td>
<td>AACGCCACGAATTTGCGT</td>
</tr>
<tr>
<td>GAPDH</td>
<td>GGGAGCACAAGGTCATCA</td>
<td>TGATGGCATGGACTGGGT</td>
</tr>
</tbody>
</table>

Table 3 Core degree of input genes in PPI network
### Figures

<table>
<thead>
<tr>
<th>Gene</th>
<th>Degree</th>
<th>Gene</th>
<th>Degree</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDM2</td>
<td>28</td>
<td>SAMD4A</td>
<td>6</td>
</tr>
<tr>
<td>ZBTB10</td>
<td>14</td>
<td>EPHA7</td>
<td>5</td>
</tr>
<tr>
<td>KLF5</td>
<td>14</td>
<td>SRGN</td>
<td>4</td>
</tr>
<tr>
<td>SRP19</td>
<td>13</td>
<td>BNC2</td>
<td>4</td>
</tr>
<tr>
<td>ID4</td>
<td>9</td>
<td>RNF19A</td>
<td>4</td>
</tr>
<tr>
<td>CPEB4</td>
<td>9</td>
<td>MKX</td>
<td>3</td>
</tr>
<tr>
<td>CPEB3</td>
<td>9</td>
<td>CUTC</td>
<td>2</td>
</tr>
<tr>
<td>ETF1</td>
<td>9</td>
<td>DIXDC1</td>
<td>2</td>
</tr>
<tr>
<td>NTNG1</td>
<td>9</td>
<td>RIC3</td>
<td>1</td>
</tr>
<tr>
<td>INHBB</td>
<td>9</td>
<td>IGF2BP3</td>
<td>1</td>
</tr>
<tr>
<td>FBXL3</td>
<td>6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 1**

SNHG1 is upregulated in bladder cancer tissues in association with poor prognosis of patients with bladder cancer. A, GEPIA (http://gepia2.cancer-pku.cn/) analysis of the location map of differentially
expressed genes obtained from BLCA data in TCGA database (https://portal.gdc.cancer.gov/). Chromosomes 1-22, X and Y were shown in turn from left to right. B, Venn diagram of the intersection of significantly differential genes obtained from GEPIA analysis, GSE65635, and GSE40355 and human lncRNA obtained from GENCODE (https://www.gencodegenes.org/human/) (intersecting genes were DIO3OS and SNHG1). C, UALCAN (http://ualcan.path.uab.edu/index.html) analysis of TCGA database showing that DIO3OS expression was significantly low in bladder cancer. D, UALCAN analysis of TCGA database showing that SNHG1 expression was significantly high in bladder cancer. E, RNA-FISH detection of SNHG1 expression in 40 cases of bladder cancer and adjacent tissues (400 ×, scale bar = 25 μm). F, RT-qPCR detection of SNHG1 expression in 40 cases of bladder cancer and adjacent tissues. G, Kaplan-Meier analysis of SNHG1 and patient survival curve.

Figure 2

Silencing SNHG1 inhibits bladder cancer cell proliferation and promotes cell apoptosis. A, RT-qPCR detecting the expression of SNHG1 in one normal urothelial cell line SV-HUC-1 and four bladder cancer cell lines (5637, T24, SW780, and UM-UC-3), and selection of T24 cells with the highest expression and 5367 cells with the lowest expression for subsequent experiments. T24 cells were transfected with si-NC or si-SNHG1. B, RT-qPCR determination of the silencing efficiency of three sh-SNHG1 in T24 cells, and screening out of the highest silencing efficiency sh-SNHG1-3. C, CCK-8 assay of the change of T24 cell viability. D, The changes of T24 cell proliferation detected by EdU assay. E, Flow cytometry analysis of the changes of T24 cell apoptosis. F, Western blot analysis of the expression of Cleaved caspase-3, Bax, and Bcl-2.
Bcl-2 in T24 cells. * p < 0.05, ** p < 0.01. The experiment was repeated three times. Data were presented as mean ± standard deviation and compared by one-way analysis of variance (ANOVA), followed by Tukey's post hoc test.

**Figure 3**

Overexpression of SNHG1 stimulates bladder cancer cell proliferation and represses cell apoptosis. 5637 cells were transfected with oe-NC or oe-SNHG1. A, RT-qPCR determination of the overexpression efficiency of oe-SNHG1 in 5637 cells. B, CCK-8 assay of the change of 5637 cell viability. C, The changes of 5637 cell proliferation detected by EdU assay. D, Flow cytometry analysis of the changes of 5637 cell apoptosis. E, Western blot analysis of the expression of Cleaved caspase-3, Bax, and Bcl-2 in 5637 cells. * p < 0.05, ** p < 0.01. The experiment was repeated three times. Data were presented as mean ± standard deviation and compared by t test.
Figure 4

SNHG1 silencing represses bladder cancer cell tumorigenesis in vivo. T24 cells stably transfected with sh-SNHG1 were subcutaneously injected into the axilla of nude mice. A, RT-qPCR to detect the expression of SNHG1 in tumors. B, Tumor weight. C, FISH to detect the expression of SNHG1 in tumors (400 ×, scale bar = 25 μm). The 5637 cells stably transfected with oe-SNHG1 were subcutaneously injected into the axilla of nude mice. D, RT-qPCR to detect the expression of SNHG1 in tumors. E, Tumor weight. F, FISH to detect the expression of SNHG1 in tumors (400 ×, scale bar = 25 μm). * p < 0.05. N = 10 mice in each group. Data were presented as mean ± standard deviation and compared by t test or repeated measures ANOVA with Tukey’s post hoc test.

Figure 5

SNHG1 binds to and downregulates miR-9-3p. A, Starbase (http://starbase.sysu.edu.cn/) website predicting that SNHG1 bound to miR-9-3p. B, RT-qPCR detecting the expression of miR-9-3p in 40 bladder cancer and adjacent normal tissues. C, Correlation analysis of the expression of SNHG1 and miR-9-3p. D, RNA pull-down assay detecting the binding relationship between SNHG1 and miR-9-3p. E, RT-qPCR detection of the expression of miR-9-3p after silencing SNHG1 in T24 cells. F, RT-qPCR detection of the
expression of miR-9-3p after overexpressing SNHG1 in 5637 cells. * p < 0.05. The experiment was repeated three times. Data were presented as mean ± standard deviation and compared by t test or one-way analysis of variance (ANOVA), followed by Tukey's post hoc test.

Figure 6

SNHG1 silencing binds to miR-9-3p to repress bladder cancer cell proliferation and tumorigenesis. T24 cells were transfected with sh-NC + inhibitor NC, sh-SNHG1 + inhibitor NC, sh-NC + miR-9-3p inhibitor, and sh-SNHG1 + miR-9-3p inhibitor. A, SNHG1 and miR-9-3p expression in T24 cells measured by RT-qPCR. B, CCK-8 assay of the change of T24 cell viability. C, The changes of T24 cell proliferation detected by EdU assay. D, Flow cytometry analysis of the changes of T24 cell apoptosis. E, Western blot analysis of the expression of Cleaved caspase-3, Bax, and Bcl-2 in T24 cells. The stably transfected T24 cells were subcutaneously injected into the axilla of nude mice. F, SNHG1 and miR-9-3p expression in mice measured by RT-qPCR. G, Tumor weight. * p < 0.05. N = 10 mice in each group. The cell experiment was repeated three times. Data were presented as mean ± standard deviation and compared by one-way analysis of variance or repeated measures ANOVA with Tukey's post hoc test.
SNHG1 silencing decreases MDM2 expression via miR-9-3p to repress bladder cancer cell proliferation and tumorigenesis. A, The downstream genes of miR-9-3p predicted by TargetScan (http://www.targetscan.org/vert_71/), DIANA TOOLS (http://diana.imis.athena-innovation.gr/DianaTools/), microRNA (http://www.microrna.org/microrna/home.do), and mirDIP (http://ophid.utoronto.ca/mirDIP/). B, The differential genes in bladder cancer obtained by GEPIA analysis of TCGA database. C, Binding sites between miR-9-3p and the 3'UTR of MDM2 predicted by TargetScan website. D, RIP experiment finding that AGO2 could pull down MDM2. E, Targeting relationship between miR-9-3p and MDM2 assessed by dual-luciferase reporter gene assay. F, The expression of MDM2 in T24 cells after silencing both SNHG1 and miR-9-3p detected by RT-qPCR. G, The expression of MDM2 in T24 cells after silencing both SNHG1 and miR-9-3p detected by western blot analysis. H, The expression of SNHG1, miR-9-3p and MDM2 after overexpressing MDM2 and silencing SNHG1 in T24 cells measured by RT-qPCR. I, CCK-8 assay of the change of T24 cell viability. J, The changes of T24 cell proliferation detected by EdU assay. K, RT-qPCR detection of the expression of SNHG1 and miR-9-3p in T24 cells. L, Tumor weight. * p < 0.05. N = 10 mice in each group. The cell experiment was repeated three times. Data were presented as mean ± standard deviation and compared by one-way analysis of variance or unpaired t test.
Figure 8

Silencing of SNHG1 decreases PPARγ ubiquitination and enhances PPARγ expression via MDM2. A, The binding of MDM2 to PPARγ detected by IP assay in T24 cells. B, Western blot analysis of the expression of MDM2 and screening of a shRNA sequence with the highest silencing efficiency. C, IP assay detecting the change of PPARγ ubiquitination after silencing MDM2. D, IP assay detecting the change of PPARγ ubiquitination after overexpressing MDM2. E, MDM2 and PPARγ expression detected by western blot analysis after overexpressing MDM2 and silencing SNHG1 in T24 cells. * p < 0.05. The cell experiment was repeated three times. Data were presented as mean ± standard deviation and compared by one-way analysis of variance.
Figure 9

Mechanism. SNHG1 promotes MDM2 expression by binding to miR-9-3p to promote PPARγ ubiquitination and downregulate PPARγ expression, thereby resulting in elevation of bladder cancer cell proliferation in vitro and tumorigenesis in vivo.